期刊
THERANOSTICS
卷 2, 期 6, 页码 541-552出版社
IVYSPRING INT PUBL
DOI: 10.7150/thno.3682
关键词
VEGF; protein delivery; cardiovascular disease; angiogenesis; tissue engineering
资金
- Spanish Ministry of Science and Innovation PSE SINBAD [PSS 0100000-2008-1]
- Caja Navarra Foundation (Programa Tu Eliges: Tu Decides)
- Spanish Ministry of Sciences and Education
- Agencia Espanola de Cooperacion Internacional para el Desarrollo (AECID)
Since the discovery of the Vascular Endothelial Growth Factor (VEGF) and its leading role in the angiogenic process, this has been seen as a promising molecule for promoting neovascularization in the infarcted heart. However, even though several clinical trials were initiated, no therapeutic effects were observed, due in part to the short half life of this factor when administered directly to the tissue. In this context, drug delivery systems appear to offer a promising strategy to overcome limitations in clinical trials of VEGF. The aim of this paper is to review the principal drug delivery systems that have been developed to administer VEGF in cardiovascular disease. Studies published in the last 5 years are reviewed and the main features of these systems are explained. The tissue engineering concept is introduced as a therapeutic alternative that holds promise for the near future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据